AngioDynamics Shares Fall On Lower Than Expected Q1 Earnings, Reaffirms Annual Guidance

• AngioDynamics Inc (NASDAQ: ANGO) has reported a Q1 FY23 adjusted EPS loss of $(0.06), missing the consensus EPS of $0.02 and lower than $(0.02) a year ago.

• Q1 sales increased 5.9% Y/Y to $81.5 million, missing the analyst consensus of $83.42 million.

• Med Tech's net sales were $22.8 million, up 29.6%, driven by Auryon sales and NanoKnife disposable sales.

• Med Device net sales were $58.7 million, a decline of 1.1% compared to the prior-year period.

• The gross margin compressed 20 bps to 51.9%, impacted by macro forces, including labor shortages and increased costs for labor, raw materials, and freight.

• Adjusted EBITDA was $3 million, compared to $3.6 million a year ago.

• Guidance: For FY23, AngioDynamics reaffirms sales of $342- $348 million versus the consensus of $344.21 million.

• The company expects a gross margin of approximately 52.5% - 54.5% and adjusted EPS of $0.01 - $0.06 (consensus of $0.02).

• Price Action: ANGO shares are down 13.02% at $18.75 on the last check Thursday.

See more from Benzinga

• Fitness Equipment Maker Peloton Lays Off Around 500 Staff To Save Its Struggling Business: Report

• Tesla To Feel Pressure After Musk's Twitter-Deal News; OPEC Output Cut Disappoints Biden; Shell Profits Low: Top Stories Thursday, Oct. 6

• Trump's Former Secretary Of State Tillerson Says Unaware That Indicted Ally Was Privy To 'Sensitive' Disc

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.